Flywheel raises $22M, buys competitor
After closing a series C round led by 8VC, Flywheel used a portion of the funds to acquire St. Louis-based Radiologics. Both have platforms to help researchers process medical imaging data.
Wugen, a biotech developing “off-the-shelf” natural killer and CAR T cell therapies, has raised $172 million in Series B financing. The company’s lead program has already reached human testing and the new capital will be used to continue that research and advance other pipeline programs to the clinic.
After Google struck a controversial partnership with Ascension to build a searchable health record, the companies are now launching an expanded clinical pilot of the tool. Now, about 250 clinicians will be able to use it.
This month, FormFast will become Interlace Health
In a recent interview, executives from two early-stage biopharma companies said that off-the-shelf approach is the only way to drive down the cost of novel cell and gene therapies like CAR-T.
The two health insurance companies signaled that they had met all regulatory requirements for the merger, including review by the Department of Justice. Centene plans to close the acquisition on Thursday.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The startup describes its software as providing clinical labs with more streamlined and accurate analysis, interpretation and reporting for accelerating personalized medicine programs.
The deal increases Centene's ownership of the Spanish provider Ribera Salud from 50 percent to 90 percent.
St. Louis, Missouri-based HarrisLogic develops clinical services and population health management software for providers, schools and law enforcement intended to help users identify potential behavioral health issues within a population and divert them appropriate resources or sites of care.
Innovations that emerge from the research will be commercialized through a joint venture between the school and Centene called the ARCH Personalized Medicine Initiative.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
As of March 4, Tamarah Duperval-Brownlee holds the newly created role of senior vice president and chief community impact officer at Ascension.
Through Epharmix, which offers condition-specific communication tools that allow care teams to remotely monitor patients, the health system can better connect with patients outside the hospital.
The network expansion represents a willingness to engage with online pharmacy businesses in order to "evolve with industry trends," according to the company.
As part of a 10-year relationship, the companies will develop the Maestro Advantage solution and Cerner will acquire a minority interest in Essence Group Holdings, Lumeris' parent company, for $266 million.
Two peer-selected startups — Advocatia and TCARE — have been named finalists of the program, which zeroes in on companies that address the needs of the aging population.